MEDI Medimmune (MM)

- Victoria McMeen, M.D., University of Virginia, Receives $35,000 Grant - TORONTO, May 7 /PRNewswire-FirstCall/ -- Underscoring its commitment to pediatric medicine, MedImmune, Inc. (NASDAQ:MEDI) has divided a 2007 grant for $210,000 for pediatric respiratory research among six pediatric fellows; each recipient's institution will receive a $35,000 grant to support the fellow's research. The Pediatric Fellowship Program, sponsored by MedImmune, is designed to stimulate interest and research in the area of viral respiratory pathogens among infectious disease fellows in the United States. The six recipients were acknowledged on Sunday, May 6, 2007 at a reception coinciding with the annual meeting of the Pediatric Academic Societies (PAS) in Toronto, Canada. "This fellowship program supports and encourages research critical to the understanding of potentially severe pediatric infectious diseases such as respiratory syncytial virus (RSV) and influenza," said Frank J. Malinoski, M.D., Ph.D., senior vice president, medical and scientific affairs. An independent advisory board consisting of 15 pediatric infectious disease physicians from across the United States selected the six fellowship recipients. All candidates were required to be full-time fellows in an American Board of Pediatrics-accredited fellowship program and conducting original research as their primary focus. The 2007 Pediatric Fellowship Program grant recipients include: -- Steven Grube, M.D. University of Texas Southwestern Medical School Project Title: The Role of Viral Persistence in Respiratory Syncytial Virus (RSV) - Induced Long Term Lung Disease -- Laura Hammitt, M.D. The Children's Hospital/University of Colorado Health Sciences Center Project Title: Vaccine-induced Immunologic Defense Against Influenza in the Respiratory Tree -- Michele Kong, M.D. University of Alabama at Birmingham, AL Project Title: Matrix Metalloproteinases and Respiratory Syncytial Virus Infection -- Jayson Luma, M.D. The Women and Children's Hospital of Buffalo Project Title: Arachidonic Acid Metabolites in Human Infants and Mouse Models of Respiratory Syncytial Virus Infection -- Victoria McMeen, M.D. University of Virginia Project Title: Viral Replication and Clearance in Asthmatic Versus Non-Asthmatic Individuals During Experimental Infections with Rhinovirus -- Archana Singh, M.D. Winthrop University Hospital Project Title: Examination of the Role of Respiratory Syncytial Virus Infection in the Pathogenesis of Lung Disease in Cystic Fibrosis MedImmune's Pediatric Fellowship Program is one example of the company's broader, ongoing commitment to research and pediatric health. In another example, the Pediatric Infectious Diseases Society (PIDS), supported by grants from MedImmune, will present the third annual MedImmune Career Development Award in Pediatric Infectious Disease and the second annual Viral Respiratory Disease Fellowship tonight at a PIDS Dinner and Awards Banquet also being held in conjunction with the PAS annual meeting. To date, MedImmune has invested more than $2 billion in research funds to develop new and next-generation medicines against respiratory viruses such as RSV and influenza. About MedImmune, Inc. MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of pediatric infectious diseases, cancer and inflammatory diseases. With more than 2,500 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company's website at http://www.medimmune.com/ . Notice to Investors and Stockholders of MedImmune This release is neither an offer to purchase nor a solicitation of an offer to sell shares of MedImmune. MedImmune stockholders are urged to read the relevant tender offer documents from AstraZeneca PLC which have been filed on May 3, 2007 because they will contain important information that stockholders should consider before making any decision regarding tendering their shares. AstraZeneca has filed tender offer materials with the U.S. Securities and Exchange Commission, and MedImmune has also filed a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the offer. The tender offer materials (including an Offer to Purchase, a related Letter of Transmittal and certain other offer documents) and the Solicitation/Recommendation Statement contain important information, which should be read carefully before any decision is made with respect to the tender offer. The Offer to Purchase, the related Letter of Transmittal and certain other offer documents, as well as the Solicitation/Recommendation Statement, are available for free at the U.S. Securities and Exchange Commission's web site at http://www.sec.gov/ , at AstraZeneca's website at http://www.astrazeneca.com/ or at MedImmune's website at http://www.medimmune.com/ . DATASOURCE: MedImmune, Inc. CONTACT: Media, Kate Barrett of MedImmune, Inc., +1-301-398-4320 Web site: http://www.medimmune.com/

Copyright